• 3-5 Impasse Reille 75014 Paris France
  • info@depixus.com

Dr Gordon Hamilton, CEO, and Dr Jimmy Ouellet, Chief Scientist of Depixus®, will be participating in the 20th Annual Discovery on Target Conference, from 17 – 20 October, in Boston.

Discovery on Target (DOT) highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules.

Depixus will be presenting a poster entitled ‘Analysis of Small Molecule Interactions on Nucleic Acid Secondary Structure: A Single Molecule Approach’.

We look forward to seeing you there!

Dr Christine Blancher, Head of Applications & Collaborations, and Dr Nigel Skinner, Head of Product Management & Marketing, of Depixus®, will be participating in the Annual ASHG Meeting, from 25 – 29 October, in Los Angeles.

The meeting provides a forum for the presentation and discussion of cutting-edge science in all areas of human genetics. ASHG members and leading scientists from around the world will be presenting their research findings at invited, plenary, platform, and poster sessions.

We look forward to seeing you there!

Dr Gordon Hamilton, CEO, Dr Steve Allen, Chief Business Officer and Dr Nigel Skinner, Head of Product Management & Marketing, of Depixus® will be participating in the 5th Annual RNA-Targeted Drug Discovery Conference, from 13 – 15 October, in Boston.

This premier, definitive, and most comprehensive forum for the RNA-targeting small molecule community will address remaining challenges, including but not limited to RNA structure and function relationship, functional validation, and the translational route from discovery to pre-clinical and clinical development.

We look forward to seeing you there!